C
hronic kidney disease (CKD) is a major complication of diabetes mellitus manifested by albuminuria, decrease in estimated glomerular filtration rate (eGFR), or both, and it occurs in up to 40% of patients with diabetes. [1] [2] [3] Although diabetic nephropathy typically is characterized by albuminuria, the degree of albuminuria and eGFR decrease at the time of initial screening often varies widely in patients with diabetes. A substantial proportion of diabetic patients do not have albuminuria despite an abnormal eGFR. Studies have found that the absence of albuminuria in patients with diabetes ranges from 30%-40% [4] [5] [6] [7] and it was reported to be as high as 55% in one study. 8 The long-term prognostic implications of albuminuria and eGFR in patients with diabetes have not been examined in a generalizable large national cohort followed up over time.
Furthermore, although both lower eGFR and greater albuminuria have been shown to independently predict poor prognosis, [1] [2] [3] [9] [10] [11] whether there is a synergistic prognostic interaction between these 2 factors in diabetic patients is largely unknown. While large population cohort studies (with a small proportion of patients with diabetes) have shown the absence of a synergistic interaction between eGFR and albuminuria, the prognostic effect of albuminuria and eGFR could be vulnerable to confounding by kidney disease type in mixed populations containing nondiabetic individuals. Thus, findings from these studies may not apply to patients with diabetes. Small studies of diabetic patients have suggested a lower risk of adverse outcomes in the absence of albuminuria 12, 13 ; however, no study has examined a large national cohort of diabetic patients.
Addressing these knowledge gaps will aid clinicians in appropriately counseling and managing diabetic patients with CKD. Specifically, it will enable clinicians to appropriately risk stratify and aggressively treat these high-risk patients and inform and educate patients regarding their prognosis. Accordingly, we studied participants with diabetes in the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) 14,15 to assess: (1) long-term prognosis by categories of albuminuria and eGFR status, and (2) whether a synergistic interaction exists between albuminuria and eGFR regarding impact on mortality and progression to end-stage renal disease (ESRD).
METHODS

KEEP Screening
KEEP is a national free community-based health screening program that targets populations at high risk of kidney disease. Enrollment has been described in detail previously.
14-18 Eligible participants are 18 years or older with self-reported diabetes or hypertension or a first-degree relative with diabetes, hypertension, or kidney disease. Participants known to have undergone kidney transplant or who have ESRD and are receiving regular dialysis are excluded. All participants provide informed consent, then complete the screening questionnaire, which includes sociodemographic information, health history, risk factors, smoking status, and information for height, weight, and blood pressure. Plasma glucose and albumin-creatinine ratio (ACR) are measured. Blood samples are drawn from consenting participants and sent to a central laboratory.
Study Design and Study Population
In this observational cohort study, our study population consisted of KEEP participants enrolled in 2000-2011, with diabetes, and for whom eGFR and albuminuria measurements were available. A total of 150,972 participants were enrolled in KEEP, and 42,761 participants with diabetes were included in this analysis. Participants were interviewed with a standardized questionnaire. Self-reported demographic characteristics included age, race, and level of education. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement checklist of items required for reporting observational studies was considered in preparation of this report.
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Variable Definitions
Diabetes was defined as history of diabetes (self-report or retinopathy), use of diabetes medications, or newly diagnosed fasting glucose level Ն126 mg/dL, nonfasting glucose level Ն200 mg/dL, or hemoglobin A 1c level Ն7%. Cardiovascular disease was defined as self-reported history of angina, heart attack, cardiac bypass surgery, coronary angioplasty, stroke, heart failure, abnormal heart rhythm, or coronary heart disease. Hypertension was defined as self-reported history of hypertension or use of antihypertensive medication. Blood pressure, height, and weight were measured by trained personnel and were categorized by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) definitions as follows: normal, systolic blood pressure (SBP) Ͻ120 mm Hg and diastolic blood pressure (DBP) Ͻ80 mm Hg; prehypertension, SBP of 120-139 mm Hg or DBP of 80-89 mm Hg; stage 1, SBP of 140-159 mm Hg or DBP of 90-99 mm Hg; and stage 2, SBP Ն160 mm Hg or DBP Ն100 mm Hg. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. Hypercholesterolemia was defined as self-reported high cholesterol level, taking medication for high cholesterol level, or total cholesterol level Ͼ200 mg/dL or triglyceride level Ͼ150 mg/dL. Anemia was defined as hemoglobin level Ͻ13 g/dL in men and Ͻ12 g/dL in women. Family history of CKD was positive if the participant identified any family members who had kidney disease or received dialysis treatment.
Laboratory Data
Measurements of serum creatinine, eGFR, and albuminuria were performed at the time of screening. GFR was estimated using the CKD Epidemiology Collaboration (CKD-EPI) equation 20 and categorized as Ն105, 90-Ͻ105, 75-Ͻ90, 60-Ͻ75, 45-Ͻ60, 30-Ͻ45, and Ͻ30 mL/min/1.73 m 2 . Albuminuria was defined from a spot urine ACR and categorized as no albuminuria (Ͻ30 mg/g), microalbuminuria (30-300 mg/g), or macroalbuminuria (Ͼ300 mg/g). Hemoglobin was measured from samples sent to a central laboratory.
Outcomes
All-cause mortality was the primary outcome of interest. Allcause mortality data were determined by linking KEEP participants to the Social Security Administration Death Master File as previously described. 21 Progression to ESRD was a secondary outcome and was determined by linking the KEEP data with the US Renal Data System data. The last date of follow-up was 
Statistical Methods
Baseline characteristics were compared for KEEP participants across categories of eGFR and ACR using analysis of variance for continuous variables and 2 test for categorical variables. We obtained locally weighted smoothing scatter plots (LOWESS 22 plots) by performing locally weighted regression of mortality and progression to ESRD of eGFR for each ACR category: Ͻ30, 30-300, and Ͼ300 mg/g. Kaplan-Meier survival analysis was conducted to examine the unadjusted association of eGFR and ACR categories with outcomes of all-cause mortality and progression to ESRD. For the mortality analysis, censoring was performed at December 31, 2011 ; for the ESRD analysis, censoring was performed at December 31, 2011 , and the date of death. Multivari- Am J Kidney Dis. 2013;61(4)(suppl 2):S12-S23 S14 Am J Kidney Dis. 2013;61(4)(suppl 2):S12-S23 S15
able Cox proportional hazards regression was used to examine independent effects of eGFR and ACR categories on all-cause mortality and progression to ESRD in separate models. All models were adjusted for the following demographic and clinical characteristics: age; sex; race; insurance status; BMI; education status; risk factors such as family history of diabetes, hypertension, and chronic kidney disease; self-reported blood pressure categorized as normal, prehypertension, stage 1, or stage 2; hyperlipidemia; smoking status; laboratory values such as hemoglobin; and medications such as oral antidiabetic medications and insulin. Both eGFR and albuminuria categories were included as dummy variables in the model, with eGFR Ն105 mL/min/1.73 m 2 and ACR Ͻ30 mg/g as the reference categories. A final model also included an eGFR (using 3 categories: Ն60, 30-59, and Յ30 mL/min/ 1.73 m 2 )-albuminuria interaction term in addition to the main effects to examine the combined effect of the 2 when adjusted for demographic and clinical factors. Relative risks are reported as hazard ratios (HRs) with 95% confidence intervals (CIs). The proportional hazards assumption for all Cox models was assessed by log-log plots and found to be true. All P values were 2 sided and P Ͻ 0.05 was considered statistically significant. All analyses were conducted in SAS (version 9.1; SAS Institute Inc). LOWESS plots were generated in STATA (version 11.1, StataCorp LP).
RESULTS
Cohort Characteristics
A total of 150,972 participants were enrolled in KEEP in 2000-2011. Excluding participants who were already receiving dialysis (n ϭ 287) left 150,685 participants, of whom 47,321 had diabetes. Excluding participants with missing values for albuminuria (n ϭ 2,624), eGFR (n ϭ 1,630), or both (n ϭ 292) and those who newly developed ESRD after enrollment but before the screening questionnaire was administered (n ϭ 14) yielded a final analytic cohort of 42,761.
Distribution of CKD
Of 42,761 participants with diabetes, 8,618 (20.2%) had eGFR Ͻ60 mL/min/1.72 m 2 and 7,715 (18.0%) had ACR Ͼ30 mg/g (Tables 1 and 2 ). Participants with GFR Ͻ60 mL/min/1.72 m 2 or ACR Ͼ30 mg/g were more likely to be older and male with more severe hypertension and poor glucose control and less likely to have a high school education ( Table 1) .
Prevalence of Albuminuria and Low eGFR
Diabetic KEEP participants had varying degrees of albuminuria and eGFR. Albuminuria was not uniformly present (Table 3 ). The prevalence of eGFR Ͻ60 mL/min/1.73 m 2 without albuminuria (ACR Ͻ30 mg/g) was 14.0% (n ϭ 5,977). Conversely, 11.9% (n ϭ 5,074) of participants had albuminuria with eGFR Ͼ60 mL/min/1.73 m 2 . Both low eGFR and albuminuria (eGFRϽ60 mL/min/1.73 m 2 and ACR Ͼ30 mg/g) occurred in 2,641 (6.2%) participants. In the lowest eGFR category, Ͻ30 mL/min/ 1.73 m 2 , the absence of albuminuria was rare, occurring in only 244 (0.57%) participants. Am J Kidney Dis. 2013;61(4)(suppl 2):S12-S23 S16
eGFR, Albuminuria, and Outcomes
Clear trends toward increasing death and higher rates of progression to ESRD occurred with lower eGFR and higher ACR. The unadjusted incidence (per 1,000 person-years) of all-cause mortality increased from 3.1 (95% CI, 2.4-3.8) in participants with eGFR Ն105 mL/min/1.73 m 2 and no albuminuria to 73.7 (95% CI, 54.9-92.5) in participants with eGFR Ͻ30 mL/min/1.73 m 2 and macroalbuminuria (P Ͻ 0.001; Table 3 ). Progression to ESRD increased from 0.2 (95% CI, 0.1-0.3) per 1,000 person-years to 220.4 (95% CI, 177.2-263.6) per 1,000 person-years (P Ͻ 0.001). Results of the LOWESS scatterplots are shown in Fig 1A and B . Probabilities of both death and progression to ESRD were higher in participants with lower eGFRs. At every eGFR value, the probabilities of death and progression to ESRD were higher with higher category of ACR. Figure 1B also shows that in participants with ACR Ͼ30 mg/g, a sharp inflection point occurred at eGFR of 40 mL/min/1.73 m 2 , showing a very high probability of progression to ESRD.
Kaplan-Meier survival analysis estimated that 10-year survival probabilities were 95.2% for eGFR Ն105 mL/min/1.73 m 2 and only 44.1% for eGFR Ͻ30 mL/min/1.73 m 2 (Fig 2A) . Survival probabilities were 87.9% for participants without albuminuria (ACR Ͻ30 mg/g) and 57.0% for those with macroalbuminuria (ACR Ͼ300 mg/g; Fig 2B) . Similarly, regarding progression to ESRD, ESRD-free probability was 99.0% for eGFR Ն105 mL/min/1.73 m 2 , but only 50.7% for eGFR Ͻ30 mL/min/1.73 m 2 ( Fig 3A) . ESRD-free probability was 99.3% for participants without albuminuria (ACR Ͻ30 mg/g), but only 68.7% for those with macroalbuminuria (ACR Ͼ300 mg/g; Fig 3B) . All log-rank test P values were Ͻ0.001 for these comparisons. These findings persisted and remained statistically significant after multivariable adjustment (Table 4) . eGFR Ͻ30 mL/min/1.73 m 2 was associated independently with mortality (HR, 1.74; 95% CI, 1.31-2.31; P Ͻ 0.001). Albuminuria was a stronger independent predictor of mortality; the HR for participants with ACR Ͼ300 mg/g was 3.20 (95% CI, 2.73-3.74). Conversely, for the outcome of progression to ESRD, eGFR Ͻ30 mL/min/1.73 m 2 was a stronger predictor (HR, 84.20; 95% CI, 46.57-152.22; P Ͻ 0.001); the HR for albuminuria was 16.88 (95% CI, 12.20-23.36; P Ͻ 0.001).
Synergistic Interaction Between Albuminuria and eGFR on Outcomes
The unadjusted interaction between eGFR and albuminuria was highly significant for mortality and progression to ESRD (P Ͻ 0.001 for both). In multivariable analyses, the interaction term of eGFR (using 3 categories: Ն60, 30-59, and Յ30 mL/min/1.73 m 2 ) with albuminuria (3 categories) remained statistically significant (P Ͻ 0.001 for outcomes of mortality and progression to ESRD). In this fully adjusted model, participants with eGFR Ͻ30 mL/min/1.73 m 2 and macroalbuminuria were 5 times more likely to die than participants with normal kidney function and no albuminuria (Table 5) . Albuminuria alone and the albuminuria-eGFR interaction were stronger predictors of long-term mortality than low eGFR (Wald 2 statistic, 8.27 for eGFR, 18.07 for albuminuria, and 15.71 for the albuminuria-eGFR interaction).
As a final note, participants with eGFR Ͻ30 mL/ min/1.73 m 2 and macroalbuminuria were at extremely high risk of developing ESRD during the median 4 Figure 1 . Probability of mortality and progression to endstage renal disease (ESRD). LOWESS is a curve-fitting technique that provides locally weighted scatterplot smoothing. These graphs are produced by the following methodology: for each participant who lived or died (y i ), a corresponding smoothed value of estimated glomerular filtration rate (eGFR; x i ) was generated. The smoothed values of eGFR were obtained by running a regression of the dependent variable (mortality; y i ) on the independent variable (eGFR; x i ) and a few data near this point. The regression was weighted so the central point (x i ; y i ) was given the highest weight, and points farther away (based on the absolute distance |x j Ϫ x ij |), less weight. The estimated regression line then was used to predict the smoothed value of eGFR. Because a separate weighted regression was performed for every point in the data, the procedure was repeated thousands of times (exactly 42,761 times) to obtain the remaining smoothed values and the curves. Abbreviation: ACR, albumincreatinine ratio.
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years of follow-up (with HRs Ͼ 1,000) compared with participants with normal kidney function and no albuminuria (Table 5) .
DISCUSSION
In this large national cohort of screened participants with diabetes, we observed varying degrees of albuminuria and eGFR. Albuminuria was absent in 14% of participants with low eGFR. Conversely, 12% of participants had albuminuria only with no decrease in eGFR. Both decreased eGFR and albuminuria were independent predictors of mortality and progression to ESRD; however, albuminuria was a stronger independent predictor of mortality, whereas decreased eGFR was a stronger predictor of progression to ESRD. Additionally, we observed a highly significant interaction between low eGFR and greater degree of albuminuria, such that the presence of both factors amplified the risk of mortality and progression to ESRD beyond what would be expected by the simple combination of their independent effects. In particular, for the outcome of progression to ESRD, the HR for the combined occurrence of albuminuria and decreased eGFR was extremely high, implying that the combination of these 2 factors practically ensured progression to ESRD.
This study has several important implications. To our knowledge, it is the first large national inception cohort study in participants with diabetes to establish Am J Kidney Dis. 2013;61(4)(suppl 2):S12-S23 S18 the independent prognostic impact of decreased eGFR and albuminuria on long-term mortality and progression to ESRD. Importantly, our study shows a strong synergistic interaction of these risk factors such that their adverse prognostic impact is amplified when both are present. This information can aid clinicians with risk stratification, facilitate appropriate counseling of patients regarding prognosis, and possibly influence the intensity of follow-up and medical management.
These data also emphasize the critical importance of albuminuria as a prognostic factor for progression to ESRD and mortality. Although both eGFR and albuminuria were associated with adverse events, albuminuria was a stronger predictor of mortality.
More importantly, the synergistic interaction we observed between albuminuria and eGFR emphasizes the importance of efforts to prevent the onset of albuminuria, detect its presence through aggressive screening and surveillance, and once it is identified, closely monitor patients for further worsening of albuminuria and kidney function.
Compared with prior studies, we observed that albuminuria is a stronger predictor of mortality than low eGFR. In prior studies, this prognostic effect of albuminuria in nondiabetic patients was much more modest (only 1.5-to 2-fold higher risk of mortality across eGFR categories). In a population-level study (with only 5% diabetic patients) by Astor et al 23 using NHANES (National Health and Nutrition Examina- tion Survey) data, the risk of death during a median follow-up of 9 years doubled in participants with albuminuria versus those without albuminuria. 23 Similarly, in a pooled meta-analysis 24 from 21 generalpopulation cohorts with a minority of diabetic patients, the long-term risk of death in the presence of albuminuria increased to twice as high as the risk without albuminuria. 24 Our study, in contrast, demonstrates that in patients with diabetes, the prognostic impact of albuminuria is much greater.
Prior studies also tried to assess the interaction between albuminuria and eGFR. [23] [24] [25] In a large pooled analysis from more than 21 population-level cohorts, the association between albuminuria and mortality remained constant and linear, independent of eGFR and conventional risk factors. 24 A large-scale epidemiologic study from NHANES also demonstrated this constant risk relationship across all eGFRs. 23 In contrast, our study shows a significant synergistic interaction between ACR and eGFR in a large diabetic Note: Both multivariable Cox proportional models adjusted for the following covariates: age, sex, race, insurance status, body mass index, education level, family history of diabetes, hypertension, chronic kidney disease, self-reported hypertension, measured blood pressure, hypercholesterolemia, smoking status, hemoglobin level, diabetes medications, and insulin use.
Abbreviations: ACR, albumin-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HR, hazard ratio. population with long-term follow-up, such that the presence of both factors amplifies the risk of adverse events.
What are potential causes of decreased eGFR in the absence of albuminuria in participants with diabetes? Numerous factors could contribute, such as interstitial renal fibrosis, atherosclerosis of the renal arteries and arterioles, and possible cholesterol emboli, which may be underappreciated and may contribute to increasing nephron loss and tubulointerstitial changes. [4] [5] [6] [7] [8] Pathology studies have identified atypical patterns of injury with renal structural changes, beyond the usual diabetic glomerulosclerosis, including tubulointerstitial changes and arteriolar hyalinosis with or without global glomerular sclerosis. 26 Despite nephron loss and tubulointerstitial changes, the absence of albuminuria may be causally related to the favorable prognosis. Albuminuria is associated with the presence of endothelial markers of vascular damage, plasma von Willebrand factor, and thrombomodulin, which have significantly higher levels in diabetic patients with albuminuria than in patients without albuminuria, independent of eGFR. [27] [28] [29] These results suggest that generalized endothelial damage in multiple vascular territories such as the heart or brain may occur in diabetic nephropathy during the microalbuminuric stage, which is not attributed to kidney damage or nephron loss per se. [27] [28] [29] In the Framingham Offspring cohort, inflammatory biomarkers such as tumor necrosis factor ␣, interleukin 6, tumor necrosis factor receptor 2, intercellular adhesion molecule 1, and osteoprotegerin were associated independently with albuminuria and levels were elevated in patients with albuminuria. 30 Inflammation is a major mediator of poor vascular outcomes and in conjunction with direct vascular damage, may explain why the absence of albuminuria is associated with favorable outcomes [4] [5] [6] [7] [8] while its presence is related to adverse events. 23, 25, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] An elegant study from the Swedish National Diabetes Register, 43 for which the aim was to identify clinical risk factors associated with the development of albuminuria and decreased kidney function in patients with type 2 diabetes, found that the development of albuminuria was associated independently with high BMI, elevated triglyceride level, low highdensity lipoprotein cholesterol level, high SBP, high hemoglobin A 1c level, smoking, and male sex (all P Ͻ 0.001). 43 Our study is consistent with this, and we also found that participants with albuminuria were more likely to have a high BMI and stage 2 hypertension and be current smokers. Thus, the risk factors associated with albuminuria are almost all modifiable. Future studies are needed to determine whether aggressive screening and timely interventions to prevent albuminuria could improve outcomes in this high-risk patient group.
Our study should be interpreted in the context of several potential limitations. First, the median duration of follow-up was 4 years. Thus, longer term risks could not be assessed. Second, we used eGFR and albuminuria measurements obtained at baseline, without subsequent repeated testing. Third, because KEEP is a screening program, some data elements are subject to patient recall. Fourth, as with any observational study, unmeasured confounding may exist despite multivariate adjustments. Fifth, eGFR was estimated using the CKD-EPI equation. 20 CKD classification among young blacks is very sensitive to the race coefficients and use of the CKD-EPI equation in KEEP, which has large racial heterogeneity, may possibly limit its generalizability to the US population. 44 Nonetheless, in KEEP as in other populations, the CKD-EPI equation has been shown to more accurately reclassify people at lower risk of CKD and death into higher eGFR categories, resulting in more accurate risk prediction. [45] [46] [47] [48] A final note is that prior studies have shown variability in ACRs on repeated ACR testing, such that ϳ50% of tested adults will not have albuminuria on repeated testing. [45] [46] [47] [48] [49] [50] [51] This could result in misclassification of the exposure variable, possibly biasing our findings toward the null. Despite this, we observed a strong independent relationship of albuminuria with adverse outcomes. Similarly, blood pressure measured at screening also could vary, possibly resulting in misclassification of hypertension as defined by the JNC 7.
In conclusion, both low eGFR and albuminuria are associated independently with higher rates of mortality and progression to ESRD in KEEP participants with diabetes. A significant synergistic interaction between lower eGFR and greater degree of albuminuria occurs in this group, such that the risk of mortality and progression to ESRD is amplified when both factors are present. Future studies are needed to determine whether early identification of modifiable risk factors for albuminuria and subsequent interventions to prevent its development can improve outcomes of patients with diabetes.
